Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Kort integrativ og neurokognitiv terapi for unge voksne med borderline personlighedsforstyrrelse (SINTYA)

10. november 2026 opdateret af: Centre Hospitalier Universitaire de Nīmes

Kort integrativ og neurokognitiv terapi for unge voksne med borderline personlighedsforstyrrelse: en undersøgelsesmodel for impulsivitetsstyring

Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

74

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Nîmes, Frankrig
        • CHU de Nîmes

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

16 år til 25 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale.
  • High BPD severity level: ZAN-BPD (score ≥ 18/36).
  • Understand, write and read French.
  • Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations.
  • Have signed the informed consent.
  • For minor patients, have signed the parental consent by at least one holder of parental authority.

Exclusion Criteria:

  • Refusal to participate.
  • Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance.
  • Intelligence quotient < 70.
  • Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).
  • Previous or current participation in specific psychotherapy for BPD.
  • Subject deprived of liberty (by judicial or administrative decision) and/or protected by law.
  • Inclusion in another study including psychotherapy for the duration of the study.
  • Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study.
  • Subject in period of exclusion from another research protocol.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Styring
Eksperimentel: SINTYA gruppe

10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Variation in explicit impulsivity between groups
Tidsramme: Baseline

UPPS-S (Impulsive Behavior Scale Short version score)

Baseline
Variation in explicit impulsivity between groups
Tidsramme: Month 4

UPPS-S (Impulsive Behavior Scale Short version score)

Month 4

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Variation in explicit impulsivity between groups
Tidsramme: Month 7

UPPS-S (Impulsive Behavior Scale Short version score)

Month 7
Variation in impulsiveness between groups
Tidsramme: Baseline

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Baseline
Variation in impulsiveness between groups
Tidsramme: Month 4

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Month 4
Variation in impulsiveness between groups
Tidsramme: Month 7

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Month 7
BPD severity level between groups
Tidsramme: Baseline

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Baseline
BPD severity level between groups
Tidsramme: Month 4

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Month 4
BPD severity level between groups
Tidsramme: Month 7

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Month 7
Emotional regulation capacities between groups
Tidsramme: Baseline

Difficulties in Emotion Regulation Scale (DERS-18)

Baseline
Emotional regulation capacities between groups
Tidsramme: Month 4

Difficulties in Emotion Regulation Scale (DERS-18)

Month 4
Emotional regulation capacities between groups
Tidsramme: Month 7

Difficulties in Emotion Regulation Scale (DERS-18)

Month 7
Dissociative symptoms between groups
Tidsramme: Baseline

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Baseline
Dissociative symptoms between groups
Tidsramme: Month 4

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Month 4
Dissociative symptoms between groups
Tidsramme: Month 7

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Month 7
Aggression between groups
Tidsramme: Baseline

Aggression Questionnaire (AQ-12)

Baseline
Aggression between groups
Tidsramme: Month 4

Aggression Questionnaire (AQ-12)

Month 4
Aggression between groups
Tidsramme: Month 7

Aggression Questionnaire (AQ-12)

Month 7
Ruminations between groups
Tidsramme: Baseline

Rumination Reflection Questionnaire (RRQ)

Baseline
Ruminations between groups
Tidsramme: Month 4

Rumination Reflection Questionnaire (RRQ)

Month 4
Ruminations between groups
Tidsramme: Month 7

Rumination Reflection Questionnaire (RRQ)

Month 7
Number of self-destructive behaviors between groups
Tidsramme: Baseline

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Baseline
Number of self-destructive behaviors between groups
Tidsramme: Month 4

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Month 4
Number of self-destructive behaviors between groups
Tidsramme: Month 7

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Month 7
Number of impulsive behaviors between groups
Tidsramme: Baseline

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Baseline
Number of impulsive behaviors between groups
Tidsramme: Month 4

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Month 4
Number of impulsive behaviors between groups
Tidsramme: Month 7

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Month 7
Level of suicide risk between groups
Tidsramme: Baseline

Columbia-Suicide Severity Rating Scale (C-SSRS)

Baseline
Level of suicide risk between groups
Tidsramme: Month 4

Columbia-Suicide Severity Rating Scale (C-SSRS)

Month 4
Level of suicide risk between groups
Tidsramme: Month 7

Columbia-Suicide Severity Rating Scale (C-SSRS)

Month 7
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: 12 Months prior to inclusion

Information taken from patient medical file

12 Months prior to inclusion
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: Baseline

Information taken from patient medical file

Baseline
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: Month 4

Information taken from patient medical file

Month 4
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: Month 7

Information taken from patient medical file

Month 7
Psychosocial functioning between groups
Tidsramme: Baseline

Functional Assessment Staging Tool (FAST)

Baseline
Psychosocial functioning between groups
Tidsramme: Month 4

Functional Assessment Staging Tool (FAST)

Month 4
Psychosocial functioning between groups
Tidsramme: Month 7

Functional Assessment Staging Tool (FAST)

Month 7
Implicit impulsivity between groups
Tidsramme: Baseline

Continuous Performance Test (CPT)

Baseline
Implicit impulsivity between groups
Tidsramme: Month 4

Continuous Performance Test (CPT)

Month 4
Implicit impulsivity between groups
Tidsramme: Month 7

Continuous Performance Test (CPT)

Month 7
Neurocognitive evaluation of implicit impulsivity between groups
Tidsramme: Baseline

Emotional Stroop (SE) customized to the study

Baseline
Neurocognitive evaluation of implicit impulsivity between groups
Tidsramme: Month 4

Emotional Stroop (SE) customized to the study

Month 4
Neurocognitive evaluation of implicit impulsivity between groups
Tidsramme: Month 7

Emotional Stroop (SE) customized to the study

Month 7
Risk taking between groups
Tidsramme: Baseline

Balloon Analogue Risk Task (BART)

Baseline
Risk taking between groups
Tidsramme: Month 4

Balloon Analogue Risk Task (BART)

Month 4
Risk taking between groups
Tidsramme: Month 7

Balloon Analogue Risk Task (BART)

Month 7
Decision making under risk conditions between groups
Tidsramme: Baseline

Game Dice Task (GDT)

Baseline
Decision making under risk conditions between groups
Tidsramme: Month 4

Game Dice Task (GDT)

Month 4
Decision making under risk conditions between groups
Tidsramme: Month 7

Game Dice Task (GDT)

Month 7

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Clémentine Estric, CHU de Nimes

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. november 2023

Primær færdiggørelse (Faktiske)

13. september 2025

Studieafslutning (Faktiske)

22. december 2025

Datoer for studieregistrering

Først indsendt

22. maj 2023

Først indsendt, der opfyldte QC-kriterier

12. juni 2023

Først opslået (Faktiske)

22. juni 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NIMAO/2022-1/CE-01

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

All IPD that underlie results in a publication

IPD-delingstidsramme

Upon publication

IPD-delingsadgangskriterier

The IPD will be made available to other researchers upon reasonable request to the corresponding author

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner